Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.40 |
| ▸ | RXRA | P19793 | 10/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30890749 | 0.91 | NR1H2 (0.42) | POLBHSD17B10NR1H2RXRANR1H3 | |
| SCHEMBL30992285 | 0.89 | IMPDH2 (0.41) | POLBHSD17B10NR1H2RXRANR1H3 | |
| SCHEMBL30890744 | 0.87 | AKR1B1 (0.35) | POLBHSD17B10NR1H2RXRANR1H3 | |
| SCHEMBL30992283 | 0.87 | CCNB2 (0.36) | NR1H2RXRANR1H3BRD4 | |
| SCHEMBL30890377 | 0.86 | MAPK1 (0.35) | NR1H2RXRANR1H3SIRT2SIRT1 | |
| SCHEMBL30890677 | 0.85 | OTUD7B (0.43) | NR1H2RXRANR1H3MAPK1KDM1A | |
| SCHEMBL30890622 | 0.85 | NR1H2 (0.38) | NR1H2RXRANR1H3BRD4CREBBP | |
| SCHEMBL30890471 | 0.84 | NR1H2 (0.41) | NR1H2RXRANR1H3 | |
| SCHEMBL30992272 | 0.84 | NR1H2 (0.43) | NR1H2RXRANR1H3BRD4CREBBP | |
| SCHEMBL30890801 | 0.83 | NR1H2 (0.37) | NR1H2RXRANR1H3BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | POLB 356/4885HSD17B10 1644/4885NR1H2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.